Serotonergic mechanisms in anxiety

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Central serotonin (5-HT) plays a key role in modulating anxiety and mediating the effects of benzodiazepines.
• The development of selective receptor subtype agonists and antagonists has renewed interest in 5-HT's role in anxiety.

Purpose of the Study:

• To review the evidence for the involvement of central 5-HT in anxiety.
• To explore the potential of novel 5-HT receptor modulators as anxiolytics.

Main Methods:

• Review of anatomical, behavioral, neurochemical, and electrophysiological evidence.
• Analysis of data from selective 5-HT receptor agonists and antagonists.
• Evaluation of preclinical and clinical studies on azapirones, 5-HT2 antagonists, and 5-HT3 antagonists.

Main Results:

• Azapirones (e.g., buspirone) acting as 5-HT1A partial agonists show anxiolytic effects in animal models and humans.
• Clinical data for 5-HT2 antagonists (e.g., ritanserin) suggest anxiolytic potential, though preclinical data are mixed.
• 5-HT3 antagonists (e.g., odansetron) demonstrate anxiolytic potential in animal models, requiring clinical confirmation.

Conclusions:

• Novel 5-HT receptor modulators, including 5-HT1A partial agonists and potentially 5-HT2 and 5-HT3 antagonists, represent promising avenues for anxiety treatment.
• Further clinical validation is necessary to confirm the therapeutic utility of 5-HT2 and 5-HT3 antagonists in managing anxiety disorders.